Edition:
United Kingdom

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

26.94USD
11 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$26.94
Open
$27.43
Day's High
$27.43
Day's Low
$26.22
Volume
162,766
Avg. Vol
285,815
52-wk High
$42.80
52-wk Low
$15.00

Latest Key Developments (Source: Significant Developments)

Heron Therapeutics Says Pricing Of An Underwritten Public Offering Of About $200 Mln Of Shares Of Common Stock
Tuesday, 26 Jun 2018 

June 25 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC SAYS PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF APPROXIMATELY $200 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Heron Therapeutics Announces Public Offering Of Common Stock
Monday, 25 Jun 2018 

June 25 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - ANNOUNCED AN UNDERWRITTEN PUBLIC OFFERING OF APPROXIMATELY $200 MILLION OF SHARES OF ITS COMMON STOCK.HERON THERAPEUTICS INC - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES OF COMMON STOCK FOR COMMERCIAL LAUNCH OF HTX-011.  Full Article

Heorn's HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
Thursday, 21 Jun 2018 

June 21 (Reuters) - Heron Therapeutics Inc ::SAYS HTX-011 FOR POSTOPERATIVE PAIN MANAGEMENT RECEIVED BREAKTHROUGH THERAPY DESIGNATION FROM U.S. FDA.HERON THERAPEUTICS-BREAKTHROUGH THERAPY DESIGNATION GRANTED FOR HTX-011 BASED ON RESULTS OF PHASE 2 STUDIES AND TWO RECENTLY COMPLETED PHASE 3 STUDIES.  Full Article

Heron Therapeutics Reports Quarterly Loss Per Share Of $0.81
Thursday, 10 May 2018 

May 10 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND RECENT CORPORATE PROGRESS.QUARTERLY LOSS PER SHARE $0.81.REAFFIRMS FULL-YEAR 2018 CINV FRANCHISE NET PRODUCT SALES GUIDANCE OF $60 MILLION TO $70 MILLION.QTRLY NET PRODUCT SALES $11.6 MILLION VERSUS $3.6 MILLION.  Full Article

Heron Therapeutics Says Enrollment Complete In Both Pivotal Phase 3 Studies For Htx-011
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS - ENROLLMENT COMPLETE IN BOTH PIVOTAL PHASE 3 STUDIES FOR HTX-011; TOP-LINE RESULTS EXPECTED IN H1 OF 2018.HERON THERAPEUTICS INC - FOR PHASE 3 EFFICACY STUDIES IN BUNIONECTOMY AND HERNIA REPAIR, EXPECTS TO FILE AN NDA WITH FDA IN H2 OF 2018.  Full Article

Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK​.  Full Article

Heron Therapeutics Announces Public Offering Of Common Stock
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES OF COMMON STOCK FOR GENERAL CORPORATE PURPOSES.  Full Article

Heron Therapeutics gets FDA approval for Cinvanti
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Heron Therapeutics Inc :Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv).U.S. Commercial launch of Cinvanti is planned for January 2018​.Remain on-track with htx-011 which we expect to file for FDA review in 2018​.  Full Article

Heron Therapeutics reports qtrly diluted net loss per share $0.77
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Qtrly basic and diluted net loss per share $0.77‍​.Heron Therapeutics Inc - ‍net product sales of Sustol for three months ended September 30, 2017 were $8.6 million​.Heron Therapeutics Inc - ‍Heron's cash, cash equivalents and short-term investments were $74.0 million as of September 30, 2017​.Heron Therapeutics Inc - ‍guidance for full-year 2017 net product sales of Sustol remains $25 million to $30 million​.  Full Article

Heron Therapeutics granted FDA fast track designation for HTX-011
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours.Heron Therapeutics Inc - ‍Phase 3 studies for HTX-011 ongoing; NDA filing planned for 2018​.Heron Therapeutics - ‍expect to report top-line results from pivotal phase 3 studies in first half of 2018 and file for FDA review in second half of 2018​.  Full Article

Israeli firm gets U.S. nod for advanced trials for non-opiate painkiller

JERUSALEM, July 10 Israeli pharmaceuticals company PainReform has received approval from the U.S. Food and Drug Administration (FDA) to begin late-stage clinical studies for a pain relief drug that is a departure from opiate-based narcotics, it said on Tuesday.